Comparative access pathways: Oregon, Canada and Australia
A practical comparison of Oregon, Canada, and Australia access pathways, and what they show about legal permission, payment, scale, and equity.
Why these pathways matter
Oregon, Canada, and Australia show three different ways to permit access before a conventional national reimbursement model exists. Oregon regulates a service model. Canada uses case-by-case special access. Australia allows prescribing through a controlled specialist pathway. None of these models solves access on its own, but each shows a different policy lever.
For readers working on reimbursement or service design, the comparison separates legal permission from practical access. A pathway can exist on paper while still being hard to use because of price, geography, trained workforce, referral rules, or uncertainty about who pays for the care around the medicine.
Oregon: regulate the service
Oregon's psilocybin framework is not a conventional medical reimbursement pathway. It regulates licensed service centres, facilitators, products, and client-facing delivery. That makes Oregon useful as a service-design precedent: it shows how a jurisdiction can define roles, training, supervision, site licensing, and operating rules even when the model sits outside ordinary insurance coverage.
The access question in Oregon is practical: who can afford the service, where centres are located, how facilitators are trained, and what follow-up support exists. A legal pathway without payment support can still concentrate access among people who can pay out of pocket.
Canada: allow exceptions for individual patients
Canada's Special Access Program can allow access to otherwise unavailable drugs for serious or life-threatening conditions when conventional options are unsuitable, unavailable, or have failed. For psychedelic therapies, this route matters because it creates a controlled exception pathway, not a broad service model.
The strength is clinical discretion in hard cases. The weakness is scale. Case-by-case access can help selected patients and generate practical experience, but it does not automatically build reimbursed services, a national therapist workforce, or consistent local availability.
Australia: govern specialist prescribing
Australia's model centres access through authorised prescribing by psychiatrists under Therapeutic Goods Administration oversight. Responsibility sits with specialist prescribers and local clinical governance rather than with a broad service-centre model.
That structure may fit medical regulation and psychiatric care better than a standalone service market. It also creates a different bottleneck: eligible prescribers, clinic capacity, governance burden, and affordability. The question is not only whether prescribing is allowed, but whether enough governed services can deliver it.
What transfers across countries
- Separate legal permission from payment, workforce, service capacity, and equity.
- Define safety roles before scaling: prescriber, therapist or facilitator, site lead, pharmacist, emergency response, and follow-up care.
- Track who actually receives care, not only how many approvals, licences, or authorised prescribers exist.
- Use early pathways to learn about delivery cost, patient selection, outcomes, safety events, and follow-up needs.
What does not transfer cleanly
No country can copy these models wholesale. Oregon's service regulation, Canada's special access mechanism, and Australia's prescribing governance each reflect local law, professional regulation, controlled-substance rules, and healthcare financing. The useful lesson is the design pattern, not the exact policy text.
Sources
- Oregon Psilocybin Services (Oregon Health Authority, 2023-01-02)
- Special Access Program for Drugs (Health Canada, 2026-04-08)
- Checklist for Prescribing Psychiatrists of Psychedelics (Therapeutic Goods Administration (TGA), 2023-09-01)
- PsyPal Guidance Paper (Version 5) (PsyPal Consortium, 2026-03-26)
This article is part of a series